Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biocept Inc BIOCQ

Healthcare Biotechnology
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular... see more

Recent & Breaking News (GREY:BIOCQ)

Biocept's Blood-based Liquid Biopsy for Non-small Cell Lung Carcinoma Highlighted in American Society of Clinical Oncology (ASCO) Abstract

Business Wire May 28, 2015

Biocept to Present at the LD Micro Invitational Conference

Business Wire May 26, 2015

Biocept Reports First Quarter 2015 Financial Results

GlobeNewswire May 12, 2015

Biocept, Inc. Schedules Webcast and Conference Call for First Quarter 2015 Financial Results

GlobeNewswire May 4, 2015

Biocept Expands Oncology Diagnostic Portfolio With Launch of c-MET Biomarker

GlobeNewswire May 4, 2015

Biocept Enters Clinical Collaboration With University of California, San Diego Moores Cancer Center

GlobeNewswire March 24, 2015

Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations

GlobeNewswire March 10, 2015

Biocept Reports Fourth Quarter 2014 Financial Results

GlobeNewswire March 9, 2015

Next Generation Sequencing Veteran Joins Biocept

GlobeNewswire March 5, 2015

Biocept to Present at the 27th Annual ROTH Conference

GlobeNewswire March 3, 2015

Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor

GlobeNewswire March 2, 2015

Biocept, Inc. Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results

GlobeNewswire February 25, 2015

Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in Patients With Metastatic Breast Cancer

GlobeNewswire February 23, 2015

Biocept, Inc. Prices $10,000,000 Public Offering

GlobeNewswire February 9, 2015

Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer

GlobeNewswire January 20, 2015

Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients

GlobeNewswire January 12, 2015

Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment

GlobeNewswire January 8, 2015

Biocept to Present at the 8th Annual OneMedForum

GlobeNewswire January 7, 2015

Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network

GlobeNewswire January 7, 2015

Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells

GlobeNewswire December 17, 2014